AAPG and 36X Related Headlines
Go Back- Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences
- Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
- Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
- Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
- Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
- Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
- ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant
- ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
- ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
- ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
- Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
- Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
- Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
- Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
- Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
- Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
- Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025
- Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
- Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
- Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
- Ascentage Pharma to Participate in Evercore China Biotech Summit
- Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025
- Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement
- Ascentage Pharma prices $192.3 million share placement at HKD68.60
- Ascentage Pharma Announces Pricing of Top-Up Placement
- Ascentage Pharma Announces Proposed Top-Up Placement
- Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
- Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
- EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
- Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
AAPG and 36X Related Press Releases
Go Back- Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences
- Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
- Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
- Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
- Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
- Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
- ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant
- ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
- ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
- ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
- Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
- Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
- Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
- Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
- Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
- Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
- Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
- Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025
- Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
- Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
- Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
- Ascentage Pharma to Participate in Evercore China Biotech Summit
- Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025
- Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement
- Ascentage Pharma Announces Pricing of Top-Up Placement
- Ascentage Pharma Announces Proposed Top-Up Placement
- Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
- Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
- EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
- Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
